Showing results (351-360 of 393) with videos related to

Sort By:
Pageof 40
Cancer Chemotherapy and Pharmacology|January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
The Oncologist|February 23, 2013
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerMichael S Lee, Harvey J Mamon, Theodore S Hong, et al.
Investigational New Drugs|January 4, 2020
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancerLipika Goyal, Surendra Pal Chaudhary, Eunice L Kwak, et al.
BMC Cancer|July 15, 2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancerJames M Cleary, Harvey J Mamon, Jackie Szymonifka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialZev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
Plos One|January 27, 2011
A new approach for heparin standardization: combination of scanning UV spectroscopy, nuclear magnetic resonance and principal component analysisMarcelo A Lima, Timothy R Rudd, Eduardo H C de Farias, et al.
ESMO Open|November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 studyJ-P Metges, K Kato, J-M Sun, et al.
European Radiology|November 7, 2019
Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methodsA de Sitter, M Visser, I Brouwer, et al.
The Lancet. Oncology|October 16, 2022
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyZev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, et al.
Pageof 40